📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
95 announcements match the current filters (relevance ≥ 5).
Biocon Completes BBL Stake Buy from Mylan for USD 200 Million; Holds ~98% Stake
Biocon Limited has completed the acquisition of the final tranche of 7,18,34,691 equity shares of Biocon Biologics Limited (BBL) from Mylan Inc. for USD 200 million. This follows the first tranche completed earlier in January 2026, bringing the total acquisition to 14,36,69,382 shares for a total cash consideration of USD 400 million. Post-acquisition, Biocon's ownership in its material subsidiary BBL has increased to approximately 98% on a fully diluted basis. This consolidation allows Biocon to have near-total control over its biologics business operations and future cash flows.
Key Highlights
Acquired final 7,18,34,691 shares of Biocon Biologics Limited from Mylan Inc.
Cash consideration for the final tranche amounted to USD 200 million.
Total acquisition cost for 14.36 crore shares stands at USD 400 million.
Biocon now holds ~98% of BBL's paid-up equity share capital on a fully diluted basis.
👀 What to Watch
Positive for long-term investors as it consolidates ownership in the high-growth biologics segment. Watch for the impact on the consolidated balance sheet and debt-to-equity ratio following the cash outflow.
Biocon Completes Rs 4,150 Crore QIP to Fully Acquire Biocon Biologics Stake
Biocon Limited has successfully raised Rs 4,150 crore (~USD 460 million) through a Qualified Institutions Placement (QIP) by issuing 11.26 crore shares at Rs 368.35 per share. The primary purpose of this fundraise is to finance the buyout of Viatris' (Mylan Inc.) stake in Biocon Biologics and to repay debt associated with this acquisition and Edelweiss CCDs. This strategic move will make Biocon Biologics a 100% wholly owned subsidiary by March 31, 2026. The QIP attracted 39 institutional investors, including major names like SBI Mutual Fund, ICICI Prudential, and JPMorgan.
Key Highlights
Raised Rs 4,150 crore through the issuance of 112,664,585 equity shares at Rs 368.35 each.
Funds will be used to acquire the remaining minority stake in Biocon Biologics from Viatris.
Aims to repay debt incurred for the acquisition of Biocon Biologics shares and Edelweiss CCDs.
The integration of Biocon Biologics as a wholly owned subsidiary is expected by March 31, 2026.
Strong institutional participation from 39 domestic and international investors.
👀 What to Watch
The successful fundraise and move to 100% ownership of the biologics business is a significant positive for long-term value unlocking. Investors should monitor the impact of debt reduction and the operational integration of the biologics unit on future earnings.
Biocon Allots 11.27 Crore Equity Shares via QIP to Raise ₹4,150 Crore
Biocon Limited has successfully completed a Qualified Institutional Placement (QIP), raising ₹41,500 million (₹4,150 crore) to strengthen its financial position. The company allotted 11,26,64,585 equity shares at an issue price of ₹368.35 per share, representing a significant capital infusion. Major institutional investors including SBI Mutual Fund and ICICI Prudential Mutual Fund participated heavily, each taking up nearly 29.5% of the total issue. This fundraise results in an equity dilution of approximately 7.47% as the total share count increases to 162.09 crore shares.
Key Highlights
Allotted 11,26,64,585 equity shares at an issue price of ₹368.35 per share
Total capital raised through the QIP amounts to ₹41,500 million (₹4,150 crore)
Paid-up equity capital increased from ₹754.12 crore to ₹810.45 crore
SBI Mutual Fund and ICICI Prudential Mutual Fund emerged as lead allottees, each securing 29.5% of the issue
The placement was completed within a two-day window from January 12 to January 14, 2026
👀 What to Watch
Investors should factor in the ~7.5% equity dilution on future EPS while noting the strong institutional backing and improved liquidity for the company. Monitor management commentary regarding the specific utilization of these funds, likely for debt reduction or biosimilar growth initiatives.
Biocon completes ₹4,150 Cr QIP; allots 11.26 Cr shares at ₹368.35 per share
Biocon Limited has successfully concluded its Qualified Institutions Placement (QIP) on January 14, 2026, raising approximately ₹4,150 crore. The company approved the allocation of 11,26,64,585 equity shares to institutional investors at a final price of ₹368.35 per share. This issue price represents a 5% discount to the regulatory floor price of ₹387.74. The successful closure and institutional participation indicate strong market confidence in the company's growth prospects.
Key Highlights
Allocated 11,26,64,585 equity shares of face value ₹5 each to qualified institutional buyers.
Issue price fixed at ₹368.35 per share, which includes a premium of ₹363.35.
The final issue price reflects a 5% discount (₹19.39) to the floor price of ₹387.74.
The total fundraise amount is approximately ₹4,150 crore based on the allotted shares and price.
The QIP was opened on January 12, 2026, and closed on January 14, 2026.
👀 What to Watch
Investors should view this as a positive liquidity event that strengthens the balance sheet, though they should account for the resulting equity dilution. Monitor management's commentary on the specific utilization of these funds for debt reduction or expansion.
Biocon Closes QIP Raising Approx ₹4,150 Crore at ₹368.35 Per Share
Biocon Limited has successfully concluded its Qualified Institutions Placement (QIP) which opened on January 12, 2026. The company's Fund Raising Committee approved the allocation of 11,26,64,585 equity shares to eligible institutional buyers. The issue price was finalized at ₹368.35 per share, representing a total fundraise of approximately ₹4,150 crore. This capital infusion is expected to strengthen the company's balance sheet and support its strategic growth initiatives.
Key Highlights
Allocation of 11,26,64,585 equity shares of face value ₹5 each to qualified institutional buyers.
Issue price fixed at ₹368.35 per share, which includes a premium of ₹363.35.
The final price represents a 5% discount to the regulatory floor price of ₹387.74 per share.
The fundraise was completed within a three-day window from January 12 to January 14, 2026.
👀 What to Watch
Investors should view this as a positive step for capital adequacy, though they should account for the equity dilution. Monitor management's commentary on the specific utilization of these funds, particularly regarding debt reduction in the biosimilars segment.
Biocon Completes ₹4,150 Crore QIP; Allocates 11.26 Crore Shares at ₹368.35
Biocon Limited has successfully closed its Qualified Institutions Placement (QIP) on January 14, 2026. The company approved the allocation of 11,26,64,585 equity shares to qualified institutional buyers at an issue price of ₹368.35 per share. This price represents a 5% discount to the floor price of ₹387.74 per share. The total capital raised through this issue is approximately ₹4,150 crore, which will likely be used to strengthen the balance sheet or fund expansion.
Key Highlights
Allocated 11,26,64,585 equity shares of face value ₹5 each to eligible QIBs
Issue price fixed at ₹368.35 per share, including a premium of ₹363.35
Applied a 5% discount to the floor price of ₹387.74 as per SEBI regulations
Total fundraise amount estimated at approximately ₹4,150 crore
Issue was opened on January 12, 2026, and closed on January 14, 2026
👀 What to Watch
Investors should view this as a positive liquidity event that strengthens Biocon's capital structure, though they should account for the equity dilution in future EPS estimates. Monitor the company's specific plans for fund deployment, particularly regarding debt reduction or biosimilar pipeline development.
Biocon Approves Interim Financial Statements for H1 FY26 Amid QIP Process
Biocon Limited has released its unaudited condensed consolidated interim financial statements for the six-month period ended September 30, 2025. This disclosure is a procedural requirement following the company's announcement regarding a Qualified Institutions Placement (QIP). The statements provide a comparative analysis against the same period in 2024 and have been reviewed by statutory auditors M/s. B S R & Co. LLP. This filing ensures financial transparency for institutional investors participating in the upcoming fundraise.
Key Highlights
Approval of unaudited condensed consolidated interim financial statements for the half-year ended September 30, 2025.
Financials include comparative data for the six-month period ended September 30, 2024.
Statements prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013.
Limited review report issued by statutory auditors M/s. B S R & Co. LLP.
Filing supports the ongoing Qualified Institutions Placement (QIP) issue opening.
👀 What to Watch
Investors should monitor the pricing and size of the QIP as these interim financials provide the basis for institutional valuation. No immediate action is required other than tracking potential equity dilution from the fundraise.
Biocon Subsidiary Receives US FDA Approval for Everolimus Tablets (2mg, 3mg, 5mg)
Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received US FDA approval for its ANDA for Everolimus Tablets for Oral Suspension. The approval covers three dosage strengths: 2 mg, 3 mg, and 5 mg, targeting the treatment of Tuberous Sclerosis Complex (TSC). This product is indicated for both adult and pediatric patients, specifically for those with Subependymal Giant Cell Astrocytoma or TSC-associated seizures. This regulatory milestone strengthens Biocon's vertically integrated drug portfolio in the critical US market.
Key Highlights
Received US FDA approval for Everolimus Tablets for Oral Suspension in 2 mg, 3 mg, and 5 mg strengths.
Indicated for TSC patients with SEGA (aged 1+) and TSC-associated partial-onset seizures (aged 2+).
Approval granted to Biocon Pharma Limited, a 100% subsidiary of Biocon Limited.
Strengthens the company's portfolio of vertically integrated drug products for international markets.
👀 What to Watch
Investors should monitor the commercial launch timeline and the potential market share Biocon can capture in this niche segment. This approval validates Biocon's R&D capabilities and supports long-term growth in its generics business.
Biocon to Expand Oncology Portfolio with Keytruda & Opdivo Biosimilars; Integration by March 2026
Biocon Biologics is expanding its oncology portfolio with three major biosimilars targeting drugs with combined 2024 sales exceeding $40 billion, including Keytruda and Opdivo. The company is on track to integrate Biocon Biologics as a wholly owned subsidiary by March 31, 2026, to streamline operations and focus on high-growth areas like GLP-1 peptides and insulins. This strategic move targets a $75 billion oncology market opportunity, representing 35% of the global pharmaceutical market. Post-integration, Shreehas Tambe will lead the combined entity as CEO & Managing Director.
Key Highlights
Unveiling biosimilars for Keytruda ($29.5B sales), Opdivo ($9.3B), and Herceptin SC ($1.72B)
Oncology portfolio now includes 17 assets, targeting an addressable market of over $75 billion
Full integration of Biocon Biologics into Biocon Ltd expected to be completed by March 31, 2026
Strategic focus on Diabetes, Oncology, and Immunology, which comprise 40% of global pharma revenue
👀 What to Watch
Investors should monitor the progress of the corporate integration and the regulatory filing timelines for the high-value oncology biosimilars. The combined focus on GLP-1 peptides and biosimilar insulins positions the company well for the growing global metabolic health market.
Biocon Consolidates Biocon Biologics Stake to 94% via Share Swap and USD 200M Cash
Biocon Limited has significantly increased its ownership in its subsidiary, Biocon Biologics Limited (BBL), to approximately 94% on a fully diluted basis. The transaction involved acquiring 26.19 crore BBL shares through a share swap, issuing 17.12 crore new Biocon shares at Rs. 405.78 each to partners including Mylan and Serum Institute. Additionally, the company completed a cash acquisition of 7.18 crore BBL shares from Mylan for USD 200 million. While this consolidates a high-growth asset, it results in an 11.36% equity dilution for existing Biocon shareholders.
Key Highlights
Acquired 33.37 crore total shares of Biocon Biologics, taking ownership to ~94% on a fully diluted basis
Issued 17.12 crore new equity shares at a preferential price of Rs. 405.78 per share
Paid USD 200 million in cash to Mylan as part of a larger USD 400 million acquisition agreement
Post-allotment, Mylan Inc. and Serum Institute hold 6.10% and 3.68% stakes in Biocon Ltd respectively
Total paid-up equity capital increased from 133.69 crore shares to 150.82 crore shares
👀 What to Watch
Investors should view the consolidation of the biologics arm as a strategic positive for long-term valuation, though they must factor in the 11% equity dilution. Monitor the company's debt profile following the USD 200 million cash payout.
Biocon Allots 17.13 Cr Shares to Consolidate Biocon Biologics Stake; Holding Reaches 94%
Biocon Limited has completed a significant consolidation of its subsidiary, Biocon Biologics Limited (BBL), by acquiring shares from Mylan, Serum Institute, and other partners. The company allotted 17.13 crore equity shares at an issue price of Rs. 405.78 per share, resulting in an 11.36% equity dilution. Additionally, Biocon paid USD 200 million in cash to Mylan for a portion of the stake. Following these transactions, Biocon's ownership in its high-growth biologics arm has increased to approximately 94% on a fully diluted basis.
Key Highlights
Allotted 17,12,79,553 equity shares at Rs. 405.78 per share on a preferential basis.
Acquired 26.19 crore BBL shares via share swap and 7.18 crore BBL shares for USD 200 million cash.
Biocon's total holding in Biocon Biologics Limited (BBL) increased to approximately 94%.
Post-allotment, Mylan Inc. holds 6.10% and Serum Institute holds 3.68% in Biocon Limited.
Total paid-up equity share capital increased from 133.70 crore to 150.82 crore shares.
👀 What to Watch
Investors should note the consolidation of the biologics business as a long-term positive for control and simplified structure, though they must account for the 11.36% equity dilution. Monitor the performance of Biocon Biologics as it now represents a much larger portion of the parent's value.
Biocon Completes Early Redemption of Rs 500 Crore NCDs
Biocon Limited has successfully completed the early full redemption of 50,000 unlisted, secured, rated, redeemable Non-Convertible Debentures (NCDs). The total value of the redemption amounts to Rs 500 Crores, with each NCD having a face value of Rs 1,00,000. The payment was executed on January 05, 2026, following Board approval granted in November 2025. This early repayment indicates a strong liquidity position and will likely reduce the company's future interest expenses.
Key Highlights
Early full redemption of 50,000 unlisted, secured, rated NCDs completed.
Total redemption amount aggregates to Rs 500 Crores.
Face value per NCD was Rs 1,00,000, originally issued in May 2023.
Payment completed on January 05, 2026, ahead of the January 31, 2026 target date.
👀 What to Watch
The early debt repayment is a positive indicator of Biocon's balance sheet strength and cash management. Investors should view this as a move to optimize capital structure and reduce interest costs.
Biocon Shareholders Approve Fundraise and Preferential Share Issuance at EGM
Biocon Limited shareholders have approved all six resolutions proposed at the Extraordinary General Meeting held on December 31, 2025. Key approvals include raising funds through equity or other securities and a preferential issuance of shares for consideration other than cash. Shareholders also authorized an increase in investment and loan limits under Section 186 and cleared material related-party transactions with Mylan Inc. While most resolutions passed with near-unanimous support, the proposal to increase investment limits saw a notable 15.67% dissent from voting participants.
Key Highlights
Approved raising funds in one or more tranches via equity or other securities with 99.13% majority support.
Passed a special resolution for the issuance of equity shares on a preferential basis for non-cash consideration with 99.73% in favour.
Authorized an increase in limits for investments, loans, and guarantees under Section 186 with 84.33% approval.
Cleared material related-party transactions with Mylan Inc. with 99.19% of non-interested votes in favour.
Total voting turnout for the meeting represented approximately 81% of the total share capital.
👀 What to Watch
Investors should monitor the upcoming details regarding the specific terms and pricing of the approved fundraise. The approval for preferential issuance and related-party transactions suggests strategic moves involving its subsidiary, Biocon Biologics.
Biocon EGM Approves Fundraise, Preferential Issue, and Mylan Related Party Transactions
Biocon Limited conducted an Extraordinary General Meeting on December 31, 2025, to pass six key resolutions focused on capital restructuring and growth. Shareholders voted on increasing the authorized share capital and raising fresh funds through equity or other securities in multiple tranches. A significant resolution involved the issuance of equity shares on a preferential basis for consideration other than cash, alongside approval for material related party transactions with Mylan Inc. These moves are designed to strengthen the balance sheet and support the strategic objectives of its subsidiary, Biocon Biologics.
Key Highlights
Approval sought for increasing the Authorised Share Capital and amending the Memorandum of Association.
Proposed raising of funds in one or more tranches through issuance of equity shares or other securities.
Issuance of Equity Shares on a preferential basis for consideration other than cash.
Approval for material related party transactions with Mylan Inc., a related party of Biocon Biologics.
Increased limits for making investments, extending loans, and providing guarantees under Section 186.
👀 What to Watch
Investors should monitor the specific terms of the fundraise and the identity of the preferential allottees to assess potential dilution. The non-cash preferential issue and Mylan transaction suggest a strategic settlement or asset acquisition that could impact long-term valuation.
Biocon Biologics Secures Full Global Rights for Biosimilar Adalimumab (Hulio)
Biocon Biologics has expanded its agreement with Fujifilm Kyowa Kirin Biologics (FKB) to secure full and exclusive global rights for Hulio (biosimilar Adalimumab). This strategic move transitions Biocon from a commercialization-only partner to an end-to-end owner responsible for manufacturing, development, and commercialization. While Biocon will pay license fees and royalties, FKB will offset certain development costs, which is expected to enhance cost efficiency and operational flexibility. This integration strengthens Biocon's immunology portfolio, which currently serves over 6.3 million patients across 120+ countries.
Key Highlights
Acquisition of full global rights for manufacturing and commercialization of biosimilar Adalimumab (Hulio).
Transition from a commercialization-only model to an end-to-end integrated model for the product.
FKB to offset certain development costs while Biocon pays technology license fees and royalties.
Strategic focus on the immunology portfolio, which currently includes three major biosimilars.
Commercial production at Biocon facilities to commence following technology transfer and regulatory approvals.
👀 What to Watch
This vertical integration is a margin-accretive move that provides Biocon with greater control over its supply chain and product development. Investors should monitor the timeline for technology transfer and regulatory approvals for the in-house manufacturing of Hulio.
Biocon Biologics Secures Full Global Rights for Biosimilar Adalimumab (Hulio)
Biocon Biologics has expanded its agreement with Fujifilm Kyowa Kirin Biologics (FKB) to secure full and exclusive global rights for Hulio (biosimilar Adalimumab). The company will now assume end-to-end responsibility for manufacturing and commercialization, moving beyond its previous role of just commercialization. This strategic shift is designed to improve cost efficiencies and provide greater flexibility in global markets. While Biocon will pay license fees and royalties, FKB will offset certain development costs, supporting the product's long-term growth.
Key Highlights
Secured full global rights for Hulio, including manufacturing and additional development responsibilities.
Agreement supersedes previous collaboration where Biocon Biologics held only commercialization rights.
Biocon Biologics will pay a technology license fee and royalties on sales to FKB for a specified tenure.
FKB will participate in development and offset certain development costs incurred by Biocon Biologics.
Strengthens Biocon's immunology portfolio, which currently serves over 6.3 million patients globally across 120+ countries.
👀 What to Watch
Investors should view this as a margin-accretive move in the long term as Biocon gains manufacturing control; monitor the timeline for regulatory approvals of the new production facilities.
Biocon Issues Commercial Papers Worth Rs 1,800 Crores at 6.85% Interest
Biocon Limited has successfully issued Commercial Papers (CP) worth Rs 1,800 Crores on a private placement basis. The short-term debt instrument carries a competitive interest rate of 6.85% and has a tenure of 88 days, maturing on March 20, 2026. The issue has been subscribed by major institutional investors including SBI Mutual Fund, Axis Mutual Fund, and Aditya Birla Sun Life. The high credit rating of IND A1+ underscores the company's strong short-term credit profile.
Key Highlights
Total issue size of Rs 1,800 Crores via private placement to mutual funds
Short-term tenure of 88 days with maturity scheduled for March 20, 2026
Competitive coupon rate of 6.85% per annum
Assigned a top-tier credit rating of IND A1+ by India Ratings
Proposed to be listed on the National Stock Exchange (NSE)
👀 What to Watch
Investors should view this as a routine short-term liquidity management exercise. The low interest rate and high credit rating indicate strong market confidence in Biocon's financial stability.
Biocon Receives US FDA EIR with VAI Status for New Jersey Generics Facility
Biocon Limited has received an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (US FDA) for its Biocon Generics Inc facility in Cranbury, New Jersey. The inspection, which took place from October 6 to October 10, 2025, resulted in a 'Voluntary Action Indicated' (VAI) status. A VAI status indicates that while some objectionable conditions were observed, the agency is not recommending any administrative or regulatory action at this time. This outcome is positive as it signifies the facility is in a state of acceptable compliance for the U.S. market.
Key Highlights
US FDA issued an Establishment Inspection Report (EIR) for the Cranbury, New Jersey facility.
The inspection was conducted over a 5-day period from October 6 to October 10, 2025.
The facility received a 'Voluntary Action Indicated' (VAI) classification, avoiding more severe regulatory sanctions.
The EIR marks the formal closure of the inspection cycle for this specific U.S.-based manufacturing site.
👀 What to Watch
Investors should view this as a positive regulatory development that reduces compliance risk for Biocon's U.S. operations. This clearance supports the company's ability to maintain supply and seek new product approvals from this facility.
Biocon Retains [ICRA]AA+ Rating; To Acquire BBL Minority Stakes for $1.17 Billion
ICRA has reaffirmed Biocon's credit rating at [ICRA]AA+ (Stable) following the company's announcement to acquire remaining minority stakes in Biocon Biologics (BBL) for $1.17 billion. The transaction involves a $773 million share swap and a $400 million cash payment, making BBL a wholly-owned subsidiary. To fund the cash component and repay existing structured debt, Biocon plans a QIP of up to Rs. 4,500 crore. This restructuring aims to simplify the group's corporate structure and consolidate BBL, which contributed 58% of consolidated revenues in FY2025.
Key Highlights
ICRA reaffirmed [ICRA]AA+ (Stable) and [ICRA]A1+ ratings for Rs. 450 crore unallocated instruments.
Acquisition of minority stakes in BBL valued at $1.17 billion from Mylan, Serum Institute, and others.
Funding includes a share swap of 171.3 million shares and $400 million cash funded via CP and a Rs. 4,500 crore QIP.
BBL is the largest revenue contributor, accounting for 58% of Biocon's consolidated revenue in FY2025.
Structured debt from the Viatris acquisition is scheduled to be repaid by January 31, 2026, using QIP proceeds.
👀 What to Watch
Investors should monitor the successful execution and pricing of the Rs. 4,500 crore QIP, as it is critical for the company's deleveraging and the BBL consolidation. The move is a long-term positive as it simplifies the corporate structure and eliminates the holding company discount.
ICRA Reaffirms Biocon's AA+ Rating; Highlights $1.17B Biocon Biologics Consolidation
ICRA has reaffirmed Biocon's credit rating at [ICRA]AA+ (Stable) following the company's announcement to acquire the remaining minority stakes in Biocon Biologics (BBL) for $1.17 billion. The transaction involves a $773 million share swap and a $400 million cash component, funded through Commercial Paper and a proposed Rs. 4,500 crore QIP. This move simplifies the group structure, making BBL—which accounts for 58% of FY25 revenues—a wholly-owned subsidiary. While consolidated leverage is expected to reduce after repaying structured debt by January 2026, the successful execution of the QIP remains a key monitorable factor.
Key Highlights
ICRA reaffirmed [ICRA]AA+ (Stable) and [ICRA]A1+ ratings for Rs. 450 crore unallocated limits.
Biocon to acquire minority stakes in Biocon Biologics for $1.17 billion, making it a 100% subsidiary.
Funding includes a Rs. 6,950 crore share swap and a $400 million cash payment.
Company plans a QIP of up to Rs. 4,500 crore to repay bridge financing and structured debt by Jan 2026.
Biocon Biologics is the largest revenue contributor, accounting for 58% of consolidated FY25 revenue.
👀 What to Watch
Investors should monitor the successful completion of the Rs. 4,500 crore QIP as it is crucial for deleveraging the balance sheet. The consolidation of the biologics business is a strategic positive that eliminates holding company discounts and simplifies the corporate structure.
